ABVX cancer bears barely relevant. reassuring signals for more stock upside later this month

Research evidence excerpt

ABVX cancer bears barely relevant. reassuring signals for more stock upside later this month

Biotechnology - Immunology

Immunology - Market Overweight

ABIVAX SA (ABVX) June 15, 2026

ABVX cancer bears barely relevant. reassuring signals for Rating:

more stock upside later this month Outperform

Price:

$96.55

The Wolfe Byte Price Target:

Part 2 data in June should be a positive update, and we see a partial stock recovery $136

% Upside:to the $110/sh range. A full recovery toward $140/sh+ is possible, but we believe 40.9%

the odds are low, because major surprises are unlikely to be part of the equation

View ABVX Model

View Comp Table

We expect Abivax to soon reverse the recent safety scare (our report). Abivax shared Company Information

details behind cancer cases and chatted with sellside today on a new educational 52-Week Range $6 - $145

primer. Data still unavailable, but the main message will likely be 'rate consistent Market Cap. (M) $7,702

with background' and 'we have nothing to hide'. Colon dysplasia will be removed. Co Shares Out. (MM) 79.8 Avg. Value Traded (MM) $116.05

will show exposure-adjusted non-NMSC & separately NSMC in (i) Part 2 (ii) combined SI% of Float 4.5%

Part 2 + Part 1 (iii) combined Ph3 + Ph2. Efficacy in non-responders and relapsers will Dividend Yield 0.0%

also be shown, but bear in mind that these could be more severe patients. Price Performance

YTD LTMWolfe opinion: investigators deeming the 2 cases "unlikely related" is the strongest 892% ABVX 1,299%

evidence, while ages (50+, 65+) and early onset (8.5mo, 6.8mo) are also redeeming. SPX 16% 20%

Priors & medical history are positive evidence, but on their own not enough to absolve

the cases. The single case from Ph2b is also 'unrelated to treatment'. NMSCs are 140